NCT05940571View on ClinicalTrials.gov

First Phase Clinical Trial of Single Agent MBF-362 in Solid Tumors

PHASE1CompletedINTERVENTIONAL

Enrollment

16

Participants

Timeline

Start Date

November 24, 2022

Primary Completion Date

November 26, 2024

Study Completion Date

January 16, 2025

Conditions

Cancer

Interventions

DRUG

MBF-362

Drug: One MBF-362 128.7 mg hard gelatin capsule EP2/EP4 antagonist 28 days single oral daily dosing cycles

Trial Locations (1)

08908

Instituto Catalan de Oncología, L'Hospitalet de Llobregat

Sponsors

Lead Sponsor

Medibiofarma S.L.

All Listed Sponsors

lead

Medibiofarma S.L.

INDUSTRY

NCT05940571 - First Phase Clinical Trial of Single Agent MBF-362 in Solid Tumors | Biotech Hunter | Biotech Hunter